Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 67, Issue 8, 2007, Pages 810-820

  Peterson, C G B ^a,d   Sangfelt, P ^a   Wagner, M ^a   Hansson, T ^a,b   Lettesjo H ^c   Carlson, M ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Thermo Fisher Scientific   (United States)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Eosinophil protein X; Inflammatory bowel diseases; Interleukin 1beta; Myeloperoxidase; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; BIOCHEMICAL MARKER; ENEMA; EOSINOPHIL PROTEIN X; INTERLEUKIN 1BETA; MESALAZINE; MYELOPEROXIDASE; PREDNISOLONE; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANAMNESIS; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COLONOSCOPY; CONTROLLED STUDY; DISEASE ACTIVITY; EOSINOPHIL; FECES ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LEUKOCYTE; MACROPHAGE; MALE; MAST CELL; MONOTHERAPY; NEUTROPHIL; PRIORITY JOURNAL; PROCTITIS; REMISSION; SIGMOIDOSCOPY; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADULT; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; ENDOSCOPY; EOSINOPHIL-DERIVED NEUROTOXIN; FECES; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; LEUKOCYTES; MALE; MIDDLE AGED; PEROXIDASE; TREATMENT OUTCOME; TRYPTASES;

EID: 36348986690     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510701452838     Document Type: Article

References (41)

1. Saverymuttu SH, Camilleri M, Rees H, Lavender JP, Hodgson HJ, Chadwick VS. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. Gastroenterology 1986;90:1121-8.
2. Izzo RS, Witkon K, Chen AI, Hadjiyane C, Weinstein MI, Pellecchia C. Interleukin-8 and neutrophil markers in colonic mucosa from patients with ulcerative colitis. Am J Gastroenterol 1992;87:1447-52.
3. Carlson M, Raab Y, Seveus L, Xu S, Hallgren R, Venge P. Human neutrophil lipocalin is a unique marker of neutrophil inflammation in ulcerative colitis and proctitis. Gut 2002;50:501-6.
4. Peterson CGB, Eklund E, Taha Y, Raab Y, Carlson M. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: Establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol 2002;97:1755-62.
5. Sugi K, Saitoh O, Hirata I, Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: Comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996;91:927-34.
6. Bischoff SC, Wedemeyer J, Herrmann A, Meier PN, Trautwein C, Cetin Y, et al. Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathology 1996;28:1-13.
7. Raab Y, Fredens K, Gerdin B, Hällgren R. Eosinophil activation in ulcerative colitis: Studies on mucosal release and localization of eosinophil granule constituents. Dig Dis Sci 1998;43:1061-70.
8. Levy AM, Gleich GJ, Sandborn WJ, Tremaine WJ, Steiner BL, Phillips SF. Increased eosinophil granule proteins in gut lavage fluid from patients with inflammatory bowel disease. Mayo Clin Proc 1997;72:117-23.
9. Carlson M, Raab Y, Peterson C, Hällgren R, Venge P. Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion. Am J Gastroenterol 1999;94:1876-83.
10. Lampinen M, Rönnblom A, Amin K, Kristjansson G, Rorsman F, Sangfelt P, et al. Eosinophil granulocytes are activated during the remission phase of ulcerative colitis. Gut 2005;54:1714-20.
11. Sarin SK, Malhotra V, Sen GS, Karol A, Gaur SK, Anand BS. Significance of eosinophil and mast cell counts in rectal mucosa in ulcerative colitis. A prospective controlled study. Dig Dis Sci 1987;32:363-7.
12. Nishida Y, Murase K, Isomoto H, Furusu H, Mizuta Y, Riddell RH, et al. Different distribution of mast cells and macrophages in colonic mucosa of patients with collagenous colitis and inflammatory bowel disease. Hepatogastroenterology 2002;49:678-82.
13. Lloyd G, Green FH, Fox H, Mani V, Turnberg LA. Mast cells and immunoglobulin E in inflammatory bowel disease. Gut 1975;16:861-6.
14. Raithel M, Winterkamp S, Pacurar A, Ulrich P, Hochberger J, Hahn EG. Release of mast cell tryptase from human colorectal mucosa in inflammatory bowel disease. Scand J Gastroenterol 2001;36:174-9.
15. Raithel M, Schneider HT, Hahn EG. Effect of substance P on histamine secretion from gut mucosa in inflammatory bowel disease. Scand J Gastroenterol 1999;34:496-503.
16. Brynskov J, Nielsen OH, Ahnfelt-Ronne I, Bendtzen K. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): A review. Dig Dis Sci 1994;12:290-304.
17. Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D. Role of interleukin 1 in inflammatory bowel disease - enhanced production during active disease. Gut 1990;31:686-9.
18. Carty E, De Brabander M, Feakins RM, Rampton DS. Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper. Gut 2000;46:487-92.
19. Saiki T, Mitsuyama K, Toyonaga A, Ishida H, Tanikawa K. Detection of pro- and anti-inflammatory cytokines in stools of patients with inflammatory bowel disease. Scand J Gastroenterol 1998;33:616-22.
20. Wedrychowicz A, Stopyrowa J, Fyderek K, Miezynski W. Stool interleukin 1beta and interleukin 1 receptor antagonist concentrations in children with active ulcerative colitis and during recovery. Eur J Pediatr 2003;162:541-2.
21. van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut 1997;40:443-8.
22. Costa JJ, Matossian K, Resnick MB, Beil WJ, Wong DTW, Gordon JR, et al. Human eosinophils can express the cytokines tumor necrosis factor-α and macrophage inflammatory protein-1α. J Clin Invest 1993;91:2673-84.
23. Bischoff SC, Lorentz A, Schwengberg S, Weier G, Raab R, Manns MP. Mast cells are an important cellular source of tumour necrosis factor alpha in human intestinal tissue. Gut 1999;44:643-52.
24. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
25. Nielsen OH, Vainer B, Madsen SM, Seidelin JB, Heegaard NH. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol 2000;95:359-67.
26. Garland CF, Lilienfeld AM, Mendeloff AI, Markowitz JA, Terrell KB, Garland FC. Incidence rates of ulcerative colitis and Crohn's disease in fifteen areas of the United States. Gastroenterology 1981;81:1115-24.
27. Binder V. A comparison between clinical state, macroscopic and microscopic appearances of rectal mucosa, and cytologic picture of mucosal exudate in ulcerative colitis. Scand J Gastroenterol 1970;5:627-32.
28. Truelove SC, Richards WC. Biopsy studies in ulcerative colitis. Br Med J 1956;1315-18.
29. Lettesjö H, Hansson T, Peterson C, Ung KA, Ringström G, Abrahamsson H, et al. Detection of inflammatory markers in stools from patients with irritable bowel syndrome and collagenous colitis. Scand J Gastroenterol 2006;41:54-9.
30. Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Shah S, Bousvaros A, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001;120:13-20.
31. Strobel S, Miller HR, Ferguson A. Human intestinal mucosal mast cells: Evaluation of fixation and staining techniques. J Clin Pathol 1981;34:851-8.
32. King T, Biddle W, Bhatia P, Moore J, Miner PB, Jr. Colonic mucosal mast cell distribution at line of demarcation of active ulcerative colitis. Dig Dis Sci 1992;37:490-5.
33. Mahida YR, Lamming CE, Gallagher A, Hawthorne AB, Hawkey CJ. 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut 1991;32:50-4.
34. Korelitz BI. An indicator of Crohn's disease activity. A need unfulfilled. J Clin Gastroenterol 1986;8:220-2.
35. Gomes P, du Boulay C, Smith CL, Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986;27:92-5.
36. Sangfelt P, Carlson M, Thörn M, Lööf L, Raab Y. Neutrophil and eosinophil granule proteins as markers of response to local prednisolone treatment in distal ulcerative colitis and proctitis. Am J Gastroenterol 2001;96:1085-90.
37. Ishiguro Y. Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J Gastroenterol 1999;34:66-74.
38. Linskens RK, Van Bodegraven AA, Schoorl M, Tuynman HA, Bartels P. Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis. Dig Dis Sci 2001;46:644-8.
39. Sands B. From symptom to diagnosis: Clinical distinctions among various forms of intestinal inflammation. Gastroenterology 2004;126:1518-32.
40. Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003;35:642-7.
41. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450-60.